Knight Therapeutics Inc. (TSX: GUD) announced today that it has fully repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin, a move that expanded its pan-American pharmaceutical footprint.
The repayment was funded through strong cash flow generated by Knight's operations in Canada and Latin America, underscoring the company's financial discipline and operational strength. Despite the repayment, the revolving credit facility remains available, providing borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. This liquidity supports Knight's ongoing growth strategy across its pan-American pharmaceutical business.
Knight Therapeutics, headquartered in Montreal, Canada, focuses on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD.
For more details on the announcement, the full press release is available at https://ibn.fm/8eluB. Additional information about Knight Therapeutics can be found at www.knighttx.com.
